AX9 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin

akebia therapeutics inc (AX9) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AKEBIA THERAPEUTICS INC (AX9)
\

Related News

No related news articles were found.

akebia therapeutics inc (AX9) Related Businessweek News

No Related Businessweek News Found

akebia therapeutics inc (AX9) Details

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

324 Employees
Last Reported Date: 03/26/19
Founded in 2007

akebia therapeutics inc (AX9) Top Compensated Officers

CEO, President & Director
Total Annual Compensation: $957.1K
Senior VP, CFO & Treasurer
Total Annual Compensation: $539.6K
Senior VP & Chief Business Officer
Total Annual Compensation: $424.0K
Compensation as of Fiscal Year 2018.
akebia therapeutics inc
Akebia Therapeutics, Inc. Announces Resignation of Scott A. Canute as Class I Director

On June 10, 2019, Scott A. Canute, a Class I Director, notified Akebia Therapeutics, Inc. of his intention to resign from the company’s Board of Directors for personal reasons, effective as of June 10, 2019. The company and Mr. Canute entered into a consulting agreement, effective as of June 10, 2019, pursuant to which Mr. Canute will provide certain consulting services to the company.

Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM

Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.

Akebia Therapeutics, Inc. Presents at Raymond James Life Sciences and MedTech Conference, Jun-19-2019 10:55 AM

Akebia Therapeutics, Inc. Presents at Raymond James Life Sciences and MedTech Conference, Jun-19-2019 10:55 AM. Venue: Lotte New York Palace hotel, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

AX9 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AX9.
View Industry Companies
 

Industry Analysis

AX9

Industry Average

Valuation AX9 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AKEBIA THERAPEUTICS INC, please visit www.akebia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.